Bristol-Myers Squibb Glucophage XR
Executive Summary
Metformin extended-release tablets approved for patients with type 2 diabetes. The product will be available in 500 mg, 850 mg and 1,000 mg tablets. Metformin immediate-release is recommended for two- or three-times daily dosing. Bristol is relying on the new formulation and its recently approved combo product Glucovance to protect its $1.9 bil. Glucophage franchise, which lost exclusivity in September
You may also be interested in...
Bristol Glucophage XR Launch Price Is 5% Discount To Metformin
Bristol-Myers Squibb is launching Glucophage XR at a 5% discount to immediate-release metformin.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011